Table 1.
mTOR inhibitors in myeloid leukemias.
| Inhibitors | Disease | Response | Reference |
|---|---|---|---|
| Rapamycin monotherapy | R/R AML | PR | Recher, et al. [102] |
| Rapamycin + MEC | R/R or untreated secondary AML | CR/PR | Perl, et al. [103] |
| Everolimus + LDAC | Naïve elderly AML | CR/Cri/PR | Wei A.H., et al. [104] |
| Temsirolimus + LDClof | R/R AML | CR/Cri | Amadori, et al. [105] |
| ATRA + LY294002 and PD98059 | APL | Increase granulocyte differentiation | Scholl S., et al. [106] |
| NVPBEZ235 + nilotinib | TKI-resistant BCR-ABL | Increase apoptosis | Airiau K., et al. [114] |
| Rapamycin + dasatinib | CML | Increase apoptosis | Pellicano F., et al. [115] |
| Resveratrol | CML | Inhibits Akt | Banerjee M. S., et al. [116] |